Meningitis Diagnostic Testing Market Size, Share & Trends Analysis Report By Test Type (Latex Agglutination Tests, Lateral Flow Assay, PCR Assay, ELISA Tests, Culture Test), By End-user, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global meningitis diagnostic testing market size was valued at USD 115.41 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 3.68% from 2023 to 2030. The increasing prevalence of meningitis and increasing favorable initiatives to combat the disease with appropriate diagnosis and treatment options are expected to boost market growth during the forecast period. According to the National Organization for Rare Disorders (NORD), in the U.S., around 2,600  people are diagnosed with bacterial meningitis each year. Moreover, according to the National Meningitis Association, around 60 0-1000 people are reported with meningococcal infections in the U.S. every year and among them, about 10-15% of people die from the disease. In addition, according to Public Health England, 461 confirmed cases of invasive meningitis were reported in the year 2020.

The increasing involvement of government bodies to control global meningococcal disorders outbreaks and the surge in the demand for rapid diagnostic systems are anticipated to fuel the market growth during the forecast period. For instance, in November 2020, WHO with its global partners engaged in meningitis control and prevention, led the development of a worldwide road map that sets a direction and vision to combat meningitis by 2030. It involved hundreds of member states representatives, partners, experts, private sector representatives as well as civil society organizations, through iterative, multidisciplinary, and comprehensive consultations. Such initiatives will increase the awareness pertaining to early diagnosis of meningitis, thereby bolstering the market growth.

In addition, active partnerships & collaborations to tackle the threat of meningococcal diseases are also expected to augment market growth. For instance, the Meningitis Research Foundation and the Global Meningococcal Initiative partnership to support and share world-class research into best practices for the diagnosis and prevention of meningitis across the globe.

Some of the common tests used for meningitis diagnosis include PCR tests, ELISA tests, lateral flow assays, culture tests, and other conventional laboratory tests such as total protein tests, CSF tests, and others. The development of novel, technologically advanced, and accurate tests are anticipated to drive market growth. Some technologically advanced tests are developed with higher sensitivity and rapid diagnosis. For instance, the QIAstat-Dx Meningitis/Encephalitis Panel developed by QIAGEN is a single rapid diagnostic test that can detect 15 microorganisms simultaneously in 1 hour.

Moreover, the ongoing research activities across the globe to develop rapid and precise diagnostic solutions for meningococcal disorders are pushing market growth forward. For instance, in February 2020, Scientists from Imperial College London received an EU grant of USD 23.5 million for five years to develop a rapid diagnostic test for meningitis and commercialize it across Europe. The most advanced feature of this investigational test is the personalized gene signatures to diagnose severe illnesses.

Furthermore, various organic and inorganic developments undertaken by leading market players to gain a competitive edge and advance their market share are likely to offer robust growth opportunities for the market during the forecast period. For instance, in January 2022, QIAGEN announced enhancements in the commercialization of its QIAstat-Dx syndromic testing solution. The enhancement allows hospitals and laboratories to test multiple pathogens from one sample. In addition, this new test allows for distinguishing between meningitis infections and GI pathogens.

Test Type Insights

Based on test type, the PCR assay segment held the largest share in 2022 attributable to factors such as the availability of a robust product portfolio of PCR tests and the high preference for PCR assays for meningitis detection due to its high accuracy. In addition, the higher sensitivity of PCR tests and the generation of highly precise and accurate results are further anticipated to increase the adoption of PCR tests for meningitis testing.

Moreover, various RT-PCR platforms are commercially available that provide results in less than two hours, including multi-target (multiplex) detection tests and single-target (singleplex) detection tests is fueling adoption for PCR assays. Moreover, technological advancements in PCR assays to reduce the turnaround time and promote precise diagnosis is also expected to offer lucrative growth opportunities to the segment. For instance, BIOFIRE FILMARRAY ME PANEL developed by bioMerieux SA allows accurate and rapid testing for common pathogens that cause a variety of CNS infections.

Whereas the lateral flow assay segment is expected to be the fastest-growing segment over the forecast period. The fastest growth of the segment is attributed to lesser cost as compared to other tests, rapid testing, and the increasing use of home-based testing. In addition, the rising demand for point-of-care testing in different healthcare facilities is also expected to support segment expansion.

End-User Insights

Hospitals segment is the leading revenue contributor in 2022 and is likely to be the highest revenue contributor in the coming years. The high prevalence of meningitis, improving healthcare coverage, increasing access to novel diagnostic technologies, and affordability are some of the factors fueling segment growth. Increasing hospitalization rates due to meningitis and the severity of the disease are expected to support the segment growth over the forecast period.

Moreover, the diagnostic centers segment held the second-highest market share and is expected to grow at a lucrative rate over the forecast period. The surge in the burden of infectious diseases along with the increasing adoption of technologically advanced products for precise and accurate results are the major factors supporting segment expansion. In addition, the segment growth is also fueled by the presence of a large number of diagnostic centers performing diagnostic tests for meningitis. For instance, ARUP Laboratories, UCSF Labs, and others are some of the diagnostic centers that offer diagnostic testing for meningitis.

Regional Insights

North America led the market in terms of revenue due to the presence of several leading players in the region and various strategic initiatives undertaken by them. In addition, the high adoption rate of advanced diagnostic devices, easy obtainability of diagnostic test kits, increasing awareness about early diagnosis, and increased number of diagnostic centers are also expected to fuel region expansion during the forecast period. Moreover, various government initiatives to promote the diagnosis of various infectious diseases are likely to offer lucrative growth opportunities during the coming years.

Asia Pacific region is projected to witness the fastest growth rate over the forecast period. The increasing incidence of meningitis, ongoing research activities, and growing economies are some of the primary factors driving the market growth. Moreover, ongoing trials in the region, favorable government initiatives, and rising investments by market players in the region are anticipated to augment region growth during the projected period.

Key Companies & Market Share Insights

Key market players in the meningitis diagnostic testing market are adopting strategies such as merger & acquisition, new product development, and partnership to increase their market share. For instance, in July 2022, Abacus Diagnostica launched GenomEra assay kit, a rapid PCR tests, in Europe for the fast detection of viruses causing meningitis and encephalitis. Moreover, in 2020, BioFire Diagnostics introduced the FilmArray ME panel in Taiwan to detect over 14 pathogens at a time.Some prominent players in the global meningitis diagnostic testing market include:

• Thermo Fisher Scientific, Inc.

• Bio-Rad Laboratories, Inc.

• Abbott

• ELITechGroup

• Seegene Inc.

• Luminex Corporation

• CERTEST BIOTEC

• IMMY

• Uniogen Oy

Meningitis Diagnostic Testing Market Report Scope

Global Meningitis Diagnostic Testing Market Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the meningitis diagnostic testing market based on test type, end-user, and region.

• Test Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Latex Agglutination Tests

  • Lateral Flow Assay

  • PCR Assay

  • ELISA Tests

  • Culture Test

  • Others

• End-User Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Diagnostic Centers

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait